Journal
JOURNAL OF MEDICINAL CHEMISTRY
Volume 61, Issue 14, Pages 6178-6192Publisher
AMER CHEMICAL SOC
DOI: 10.1021/acs.jmedchem.8b00613
Keywords
-
Categories
Funding
- Department of Defense (DoD) [PR151090]
- Congressionally Directed Medical Research Programs (CDMRP)
- Stanford SPARK program
- Agency for Innovation by Science and Technology in Flanders [IWT.141103]
- Child Health Research Institute
- Lucile Packard Foundation for Children's Health
- Stanford CSTA [UL1 TR000093]
Ask authors/readers for more resources
There is an urgent need for strategies to combat dengue and other emerging viral infections. We reported that cyclin G-associated kinase (GAK), a cellular regulator of the clathrin-associated host adaptor proteins AP-1 and AP-2, regulates intracellular trafficking of multiple unrelated RNA viruses during early and late stages of the viral lifecycle. We also reported the discovery of potent, selective GAK inhibitors based on an isothiazolo[4,3-b]pyridine scaffold, albeit with moderate antiviral activity. Here, we describe our efforts leading to the discovery of novel isothiazolo[4,3-b]pyridines that maintain high GAK affinity and selectivity. These compounds demonstrate improved in vitro activity against dengue virus, including in human primary dendritic cells, and efficacy against the unrelated Ebola and chikungunya viruses. Moreover, inhibition of GAK activity was validated as an important mechanism of antiviral action of these compounds. These findings demonstrate the potential utility of a GAK-targeted broad-spectrum approach for combating currently untreatable emerging viral infections.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available